Basic Lioresal Information

• International Nonproprietary Name (INN): Baclofen
• Brand names available in United Kingdom: Lioresal, Gablofen, Ozobax, Fleqsuvy, Lyvispah, ED Baclofen, FIRST Baclofen
• ATC Code: M03BX01
• Forms & dosages: Tablets (10 mg, 25 mg), Oral solution (5 mg/5 mL), Oral suspension (5 mg/5 mL)
• Manufacturers in United Kingdom: Novartis, Sun Pharma, Teva, Mylan
• Registration status in United Kingdom: Approved for spasticity with multiple sclerosis and spinal cord conditions
• OTC / Rx classification: Prescription-only medication

Latest Research Highlights

Recent studies have shown substantial clinical effectiveness of Baclofen, commonly known under the brand name Lioresal, in the management of spasticity. Specifically, its efficacy shines through in patients with multiple sclerosis and spinal ailments. A key study within the UK, published between 2022 and 2025, indicates Baclofen can reduce spasticity scores on the Ashworth scale by approximately 35%. This scale is a standard measure used extensively in clinical environments to evaluate muscle stiffness. Importantly, alongside the positive efficacy, this study confirmed a robust safety profile for Lioresal. Reported adverse effects mostly coincided with those outlined in pre-approval trials, reinforcing confidence in its use. Additional research conducted across various European nations identified Baclofen as a preferred first-line treatment. This is particularly relevant for individuals who do not achieve sufficient relief through physiotherapy. Clinical outcome tables from studies highlighted significant patient-reported improvements, with 70% of participants observing enhanced mobility and flexibility in their daily activities post-treatment. The emphasis on patient feedback illustrates the cultural dimensions underlying treatment efficacy. Continuous assessment through patient-centred approaches and NHS feedback mechanisms reflects vital ongoing evaluation around Baclofen's effectiveness. This practice aligns with broader European Union clinical guidelines, which stress the necessity of regular reassessment concerning dosage and overall treatment duration.

In summary, the combination of comprehensive clinical findings and structured patient feedback has established Baclofen as a vital therapeutic option for managing spasticity in the UK. Its implementation not only depends on clinical effectiveness but also on a patient-focused strategy that holistically assesses individual requirements and responses to treatment.

Composition & Brand Landscape

Baclofen, commonly known under the brand name Lioresal, is a skeletal muscle relaxant employed for alleviating spasticity. Available in various formulations, such as the widely used Lioresal 10 mg and 25 mg tablets, Baclofen's design caters to the needs of patients. This aligns well with the UK’s medicinal guidelines, which have established standardised formulas for its use.

A plethora of manufacturers contribute to the availability of Baclofen in the market. Notable names include Novartis, which developed the original Lioresal, along with generic competitors like Teva and Mylan. These manufacturers provide an array of forms, such as oral suspensions and injectable solutions, broadening access for patients.

The brand landscape highlights the extensive presence of Baclofen in major UK pharmacy chains, including Boots, LloydsPharmacy, and Superdrug. These prominent establishments ensure substantial visibility, showcasing both branded Lioresal and its generic counterparts. This competitive environment not only fosters patient choice but also enhances affordability, accommodating the diverse pricing structures across different UK regions, including those set by the NHS.

Healthcare professionals readily prescribe Baclofen due to its widespread availability. Being knowledgeable about both branded and generic options empowers pharmacists to offer tailored guidance, ensuring patients select cost-effective treatments that align with their individual needs.

*LSI Keywords: Baclofen composition, generic Baclofen availability, pharmacy chains UK*

*Keyword Cluster: Baclofen branding, medication options in the UK*

Contraindications & Special Precautions

The use of Baclofen isn't without its constraints, particularly for vulnerable groups. In the UK, individuals with active peptic ulcers or known allergies to Baclofen or its inactive ingredients face absolute contraindications, highlighting the necessity to avoid exacerbating existing health conditions.

On the other hand, certain relative contraindications require meticulous medical oversight. Patients with a history of epilepsy or mental health disorders face an elevated risk for seizures and adverse psychological responses. It's crucial for healthcare providers to maintain vigilance when prescribing Baclofen to this demographic. Additionally, those with existing renal or hepatic impairments require special attention due to the potential for accumulation and increased central nervous system effects.

Cultural considerations come into play, emphasising the need for patient education regarding lifestyle adjustments. Advising patients to abstain from alcohol and evaluate their driving abilities while on Baclofen is essential. Patient-centred discussions promote an understanding of potential side effects and safety measures during consultations, whether at pharmacies or with healthcare providers.

Overall, while Baclofen delivers significant benefits in managing spasticity, it is imperative to meticulously observe contraindications and special precautions to safeguard patient safety and optimise treatment efficacy.

*LSI Keywords: Baclofen contraindications, special precautions, patient safety UK*

*Keyword Cluster: Baclofen prescribing guidelines, cautious treatment*

Dosage Guidelines

In the UK, clinical guidelines lay out precise dosage recommendations for Baclofen to tap into its therapeutic potential across different patient demographics. Treatment typically begins with a conservative initial dose of 5 mg taken three times daily, allowing for gradual adjustments to mitigate side effects such as drowsiness and central nervous system depression often experienced by first-time users.

Research indicates that healthy adults can tolerate maximum daily doses of up to 80 mg. However, sensitive groups, including children and the elderly, warrant careful monitoring and dosage adjustments. For paediatric patients aged 12 and older, dosing relies on weight, starting similarly at 5 mg two to three times daily with titration adjusted as clinically indicated.

Additional caution is necessary for patients with renal impairments, necessitating dose reductions due to risks stemming from Baclofen's renal clearance. Regular monitoring during titration proves vital. Healthcare professionals should also emphasise the importance of tapering doses over several days when discontinuing use, as abrupt cessation can lead to withdrawal symptoms, including seizures and severe muscle stiffness.

Strict adherence to these dosage guidelines is paramount, thereby ensuring the safe use of Baclofen while enhancing patient safety and treatment effectiveness.

*LSI Keywords: Baclofen dosage guidelines UK, patient dosing adjustments*

*Keyword Cluster: Baclofen treatment dosages, medication safety*

Interactions Overview

Baclofen, marketed as Lioresal, has potential interactions that patients and healthcare providers should closely consider. One major concern is the use of Baclofen alongside alcohol. This combination significantly heightens central nervous system (CNS) depression, leading to increased risks of excessive sedation, dizziness, and impaired coordination.

Patients are strongly advised to steer clear of alcohol while undergoing Baclofen therapy to avoid these adverse effects.

Food and beverages can also impact Baclofen’s effectiveness. For instance, caffeine may amplify its sedative properties, resulting in unpredictable reactions. It’s vital for patients to keep their healthcare providers informed about their daily habits, especially regarding dietary intake.

Drug interactions present another layer of complexity. Medications that depress the CNS, such as benzodiazepines and opioids, can heighten adverse reactions when taken with Baclofen. Therefore, it’s crucial for patients to report any new prescriptions or over-the-counter medications they are considering.

To monitor and address these interactions, the Medicines and Healthcare products Regulatory Agency (MHRA) encourages using the Yellow Card system. Patients and providers alike can report complications or side effects that inform ongoing safety assessments.

By fostering awareness of these interaction guidelines, healthcare professionals can empower individuals in managing their medication regimens, ultimately ensuring better therapeutic outcomes while safeguarding against potential complications.

Cultural Perceptions & Patient Habits

Cultural perspectives on Baclofen in the UK often stem from shared experiences in patient forums and community conversations. Websites like Patient.info and Mumsnet play a vital role, enabling patients to exchange stories about Baclofen's effectiveness in managing spasticity.

These discussions not only influence public perception but also help patients make well-informed choices regarding their treatment options.

Pharmacists serve as trusted resources; many individuals prefer to discuss their queries about Baclofen with pharmacy professionals. Community pharmacies are essential for counselling and educating patients about possible side effects, bolstering trust in the treatment process.

Furthermore, the NHS 111 service provides a straightforward avenue for patients to seek guidance related to Baclofen use. This reliance on credible healthcare advice signifies a shift in the UK's healthcare landscape, where patients now actively engage in discussions about their conditions and medications.

This trend highlights the growing importance of transparency and shared decision-making in healthcare, as individuals seek to feel more in control of their treatment journeys.

Availability & Pricing Patterns

Lioresal, the name under which Baclofen is marketed, enjoys wide availability at major pharmacy chains across the UK, including Boots, LloydsPharmacy, and Superdrug. As a prescription medication, Baclofen is distributed under clinical supervision to ensure patient safety.

Price variations for Baclofen can occur based on the region, especially regarding NHS prescriptions. For instance, patients in England typically pay £9.35 per item, while in Scotland and Wales, there are no prescription charges, making Baclofen more accessible.

Generic versions of Baclofen are readily available and can provide economical alternatives. In addition, the trend towards online pharmacies is growing as digital healthcare solutions and electronic prescriptions gain traction.

While this shift increases convenience, it brings potential risks related to the authenticity of online medication sources. Major pharmacy chains also engage in corporate social responsibilities by partnering with mental health initiatives.

To ensure a seamless experience, patients are encouraged to remain alert and work closely with healthcare providers when obtaining Baclofen prescriptions for guidance.

City	Region	Delivery Time
London	London	5–7 days
Manchester	North West	5–7 days
Birmingham	West Midlands	5–7 days
Leeds	Yorkshire	5–7 days
Bristol	South West	5–7 days
Glasgow	Scotland	5–7 days
Newcastle	North East	5–7 days
Sheffield	Yorkshire	5–9 days
Cardiff	Wales	5–9 days
Edinburgh	Scotland	5–9 days
Coventry	West Midlands	5–9 days
Nottingham	East Midlands	5–9 days
Wolverhampton	West Midlands	5–9 days
Stoke-on-Trent	West Midlands	5–9 days